Drug vectorization

P Couvreur. Nanoparticulate drug vectors [in French). In Buri P.. Fhiisieux F.. Doelker E., Benoit J.P. eds. New pharmaceutical forms. Pari.s Lavoisier Tec Doc, 1985, pp 577-61 I,... 

Magnetic carriers for drug vectorization The particles are loaded with the active pharmaceutical substance and directed by means of a magnetic field gradient toward the desired location in the body. 

The nasal tissue is highly vascularized and provides efficient systemic absorption. Compared with oral or subcutaneous administration, nasal administration enhances bioavailability and improves safety and efficacy. Chitosan enhances the absorption of proteins and peptide drugs across nasal and intestinal epithelia. Gogev et al. demonstrated that the soluble formulation of glycol chitosan has potential usefulness as an intranasal adjuvant for recombinant viral vector vaccines in cattle [276]. 

Zernov VV, Balakin KV, Ivaschenko AA, Savchuk NP, Pletnev IV. Drug discovery using support vector machines. The case studies of drug-likeness, agrochemical-likeness, and enzyme inhibition predictions. J Chem Inf Comput Sci 2003 43(6) 2048-56. 

Paciotti, G.F., Myer, L., Weinreich, D., Goia, D., Pavel, N., McLaughlin, R.E. and Tamarkin, L. (2004) Colloidal gold a novel nanoparticle vector for tumor directed drug delivery. Drug Delivery, 11, 169-183. 

HIV phenotype A type of resistance testing for human immunodeficiency virus (HIV) in which a patient s blood sample is obtained, and the patient s HIV genes that encode for reverse transcriptase and protease are removed and placed in an HIV viral vector. This viral vector is replicated in a cell culture system with varying concentrations of antiretrovirals. A drug concentration-viral inhibition curve is developed and the concentration needed to inhibit 50% of the patient s virus is reported. This is used to predict resistance versus susceptibility. 

---